Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 4×
“In large randomized trials, oral TKIs erlotinib and lapatinib have been found to cause diarrhea in 40–60% of patients with approximately 10% experiencing grade 3 or 4 toxicity [11, 14].”
BackgroundMethodInfluentialCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 2×
“Allergic and anaphylactoid reactions are associated with cetuximab and, less often, panitumumab administration [26, 75].”
BackgroundMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 9×
“Cetuximab with radiotherapy versus radiotherapy alone was also studied in a separate phase III trial.”
BackgroundMethodInfluentialEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“Hindawi Publishing Corporation Journal of Oncology Volume 2009, Article ID 567486, 14 pages doi:10.1155/2009/567486”
BackgroundInfluentialKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · cited 17×
“In 1,217 patients, the study compared gefitinib monotherapy to carboplatin/paclitaxel (C/P) in chemonaive never- or light-exsmokers with advanced NSCLC with adenocarcinoma histology (Table 2).”
BackgroundMethodInfluentialVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“In another large phase III randomized trial of previously untreated advanced NSCLC, the combination of carboplatin and paclitaxel with or without erlotinib was evaluated.”
BackgroundCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 6×
“NSCLC Carboplatin, Paclitaxel +/− Erlotinib [11] 1059 pts Previously untreated”
BackgroundResultInfluentialHidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Management and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“Anti-EGFR therapy generally improves survival in EGFR-positive cancer patients [377].”
BackgroundPeterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., & Herrstedt, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv202 · Cited by 299
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., Wang, L., Gooding, W. E., Johnson, D. E., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0792 · Cited by 158
Metadata
- Authors
- Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A.
- Venue
- Journal of Oncology
- Publisher
- Hindawi Limited
- Published
- 2009
- Volume
- 2009
- Pages
- 1-14
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- OpenAlex
- W2034287995
- Cited by
- 116
- References
- 16
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.